References
- Frischer JM, Weigand SD, Guo Y, et al. Clinical and pathological insights into the dynamic nature of the white matter multiple sclerosis plaque. Ann Neurol. 2015;78(5):710–721.
- Luchetti S, Fransen NL, Van Eden CG, et al. Progressive multiple sclerosis patients show substantial lesion activity that correlates with clinical disease severity and sex: a retrospective autopsy cohort analysis. Acta Neuropathol. 2018;135(4):511–528.
- Dal-Bianco A, Grabner G, Kronnerwetter C, et al. Slow expansion of multiple sclerosis iron rim lesions: pathology and 7 T magnetic resonance imaging. Acta Neuropathol. 2017;133(1):25–42.
- Dal-Bianco A, Grabner G, Kronnerwetter C, et al. Long-term evolution of multiple sclerosis iron rim lesions in 7 T MRI. Brain. 2021;144(3):833–847.
- Filippi M, Bruck W, Chard D, et al. Association between pathological and MRI findings in multiple sclerosis. Lancet Neurol. 2019;18(2):198–210.
- Absinta M, Sati P, Masuzzo F, et al. Association of chronic active multiple sclerosis lesions with disability in vivo. JAMA Neurol. 2019;76(12):1474–1483.
- Absinta M, Sati P, Gaitan MI, et al. Seven-tesla phase imaging of acute multiple sclerosis lesions: a new window into the inflammatory process. Ann Neurol. 2013;74(5):669–678.
- Absinta M, Sati P, Schindler M, et al. Persistent 7-tesla phase rim predicts poor outcome in new multiple sclerosis patient lesions. J Clin Invest. 2016;126(7):2597–2609.
- Filippi M, Preziosa P, Barkhof F, et al. Diagnosis of progressive multiple sclerosis from the imaging perspective: a review. JAMA Neurol. 2021;78(3):351–364.
- Chawla S, Kister I, Sinnecker T, et al. Longitudinal study of multiple sclerosis lesions using ultra-high field (7T) multiparametric MR imaging. PLoS One. 2018;13(9):e0202918.
- Kaunzner UW, Kang Y, Zhang S, et al. Quantitative susceptibility mapping identifies inflammation in a subset of chronic multiple sclerosis lesions. Brain. 2019;142(1):133–145.
- Tolaymat B, Zheng W, Chen H, et al. Sex-specific differences in rim appearance of multiple sclerosis lesions on quantitative susceptibility mapping. Mult Scler Relat Disord. 2020;45(102317).
- Elliott C, Belachew S, Wolinsky JS, et al. Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis. Brain. 2019;142(9):2787–2799.
- Elliott C, Wolinsky JS, Hauser SL, et al. Slowly expanding/evolving lesions as a magnetic resonance imaging marker of chronic active multiple sclerosis lesions. Mult Scler. 2019;25(14):1915–1925.
- Preziosa P, Pagani E, Moiola L, et al. Occurrence and microstructural features of slowly expanding lesions on fingolimod or natalizumab treatment in multiple sclerosis. Mult Scler. 2020;1352458520969105.
- Kaunzner UW, Kang Y, Monohan E, et al. Reduction of PK11195 uptake observed in multiple sclerosis lesions after natalizumab initiation. Mult Scler Relat Disord. 2017;15:27–33.
- Sucksdorff M, Rissanen E, Tuisku J, et al. Evaluation of the effect of fingolimod treatment on microglial activation using serial PET imaging in multiple sclerosis. J Nucl Med. 2017;58(10):1646–1651.
- Sucksdorff M, Tuisku J, Matilainen M, et al. Natalizumab treatment reduces microglial activation in the white matter of the MS brain. Neurol Neuroimmunol Neuroinflamm. 2019;6(4):e574. DOI: https://doi.org/10.1177/1352458520969105.
- Eisele P, Kraemer M, Dabringhaus A, et al. Characterization of chronic active multiple sclerosis lesions with sodium ((23) Na) MRI - preliminary observations. Eur J Neurol. 2021;28(7):2392–2395.
- Tolebrutinib, a brain-penetrant bruton s tyrosine kinase inhibitor, for the modulation of chronically inflamed white matter lesions in multiple sclerosis. Available at https://clinicaltrials.gov/ct2/show/study/NCT04742400. Access date 2021 Apr 20th.
- Hogel H, Rissanen E, Vuorimaa A, et al. Positron emission tomography imaging in evaluation of MS pathology in vivo. Mult Scler. 2018;24(11):1399–1412.
- Elliott C, Arnold DL, Chen H, et al. Patterning chronic active demyelination in slowly expanding/evolving white matter MS lesions. AJNR Am J Neuroradiol. 2020;41(9):1584–1591.